Cargando…

SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon

The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon...

Descripción completa

Detalles Bibliográficos
Autores principales: Nwosu, Kene, Fokam, Joseph, Wanda, Franck, Mama, Lucien, Orel, Erol, Ray, Nicolas, Meke, Jeanine, Tassegning, Armel, Takou, Desire, Mimbe, Eric, Stoll, Beat, Guillebert, Josselin, Comte, Eric, Keiser, Olivia, Ciaffi, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494753/
https://www.ncbi.nlm.nih.gov/pubmed/34615863
http://dx.doi.org/10.1038/s41467-021-25946-0
_version_ 1784579383874289664
author Nwosu, Kene
Fokam, Joseph
Wanda, Franck
Mama, Lucien
Orel, Erol
Ray, Nicolas
Meke, Jeanine
Tassegning, Armel
Takou, Desire
Mimbe, Eric
Stoll, Beat
Guillebert, Josselin
Comte, Eric
Keiser, Olivia
Ciaffi, Laura
author_facet Nwosu, Kene
Fokam, Joseph
Wanda, Franck
Mama, Lucien
Orel, Erol
Ray, Nicolas
Meke, Jeanine
Tassegning, Armel
Takou, Desire
Mimbe, Eric
Stoll, Beat
Guillebert, Josselin
Comte, Eric
Keiser, Olivia
Ciaffi, Laura
author_sort Nwosu, Kene
collection PubMed
description The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29·2% (95% CI 24·3–34·1). This is about 322 times greater than the 0.09% nationwide attack rate implied by COVID-19 case counts at the time. Men, obese individuals and those living in large households were significantly more likely to be seropositive, and the majority (64·2% [58·7–69·4]) of seropositive individuals reported no symptoms. Despite the high seroprevalence, most of the population had not been infected with SARS-CoV-2, highlighting the importance of continued measures to control viral spread and quick vaccine deployment to protect the vulnerable.
format Online
Article
Text
id pubmed-8494753
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84947532021-10-07 SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon Nwosu, Kene Fokam, Joseph Wanda, Franck Mama, Lucien Orel, Erol Ray, Nicolas Meke, Jeanine Tassegning, Armel Takou, Desire Mimbe, Eric Stoll, Beat Guillebert, Josselin Comte, Eric Keiser, Olivia Ciaffi, Laura Nat Commun Article The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29·2% (95% CI 24·3–34·1). This is about 322 times greater than the 0.09% nationwide attack rate implied by COVID-19 case counts at the time. Men, obese individuals and those living in large households were significantly more likely to be seropositive, and the majority (64·2% [58·7–69·4]) of seropositive individuals reported no symptoms. Despite the high seroprevalence, most of the population had not been infected with SARS-CoV-2, highlighting the importance of continued measures to control viral spread and quick vaccine deployment to protect the vulnerable. Nature Publishing Group UK 2021-10-06 /pmc/articles/PMC8494753/ /pubmed/34615863 http://dx.doi.org/10.1038/s41467-021-25946-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Nwosu, Kene
Fokam, Joseph
Wanda, Franck
Mama, Lucien
Orel, Erol
Ray, Nicolas
Meke, Jeanine
Tassegning, Armel
Takou, Desire
Mimbe, Eric
Stoll, Beat
Guillebert, Josselin
Comte, Eric
Keiser, Olivia
Ciaffi, Laura
SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
title SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
title_full SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
title_fullStr SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
title_full_unstemmed SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
title_short SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
title_sort sars-cov-2 antibody seroprevalence and associated risk factors in an urban district in cameroon
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494753/
https://www.ncbi.nlm.nih.gov/pubmed/34615863
http://dx.doi.org/10.1038/s41467-021-25946-0
work_keys_str_mv AT nwosukene sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT fokamjoseph sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT wandafranck sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT mamalucien sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT orelerol sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT raynicolas sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT mekejeanine sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT tassegningarmel sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT takoudesire sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT mimbeeric sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT stollbeat sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT guillebertjosselin sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT comteeric sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT keiserolivia sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon
AT ciaffilaura sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon